Leukemia, like lymphoma and multiple myeloma, is a cancer of the blood and bone marrow and is one of the most common cancers among 9/11 responders and survivors. Many types of blood cancers are covered by the World Trade Center Health Program (WTCHP) and are included on the List of WTC-Related Health Conditions. For those who are suffering from one particular type of leukemia, a new drug recently approved by the U.S. Food and Drug Administration offers hope for more effective treatment.

Leukemia begins in cells in the bone marrow. Over time, the leukemia cancer cells suppress the development of normal cells. There are different types of leukemia, and the rate at which leukemia develops and how the cells replace the normal blood and marrow cells are different with each type of leukemia. 

One type of 9/11-related leukemia is called acute myeloid leukemia (AML). One of the most common leukemias in adults, AML is diagnosed in nearly 15,000 people in the United States each year. The average age at diagnosis is 67, and is more common in men than women.

Earlier this year, the FDA approved the drug Enasidenib (Idhifa®) for the treatment of AML that has stopped responding to other therapies. According to Memorial Sloan Kettering Cancer, which provided key research support behind the FDA’s approval of the drug:

“Enasidenib is the first drug of its kind to be approved for any cancer. Rather than kill cancer cells, Enasidenib rehabilitates them. It allows them to develop as normally functioning blood cells, reversing a stalled developmental state that causes the cells to behave as wayward miscreants. This makes the treatment much less toxic.”

Treatment of AML using this new drug may be available at no cost through the WTCHP. The WTCHP will cover all medically necessary diagnostic evaluation and cancer treatment costs for certified conditions, including:

  • Inpatient hospitalization
  • Inpatient surgeries
  • Outpatient procedures
  • Chemotherapy
  • Prescription medications

If you have recently been diagnosed with cancer that you believe is related to 9/11 and you haven’t already enrolled in the World Trade Center Health Program, you should do so immediately. Enrolling in the WTCHP is the first step towards receiving treatment for cancers covered by the Zadroga Act, including leukemia.

Since the passage of the original Zadroga Act in 2010, the 9/11 cancer compensation attorneys at Turley Hansen & Partners have recovered over $75 million in 9/11 victim compensation for over 1200 clients, including hundreds of cancer patients and their families. We are the only law firm in the country that focuses exclusively on representing victims and first responders for their 9/11 related cancers, illnesses and injuries. Please call us at 1-855-WTC-INFO (982-4636) or fill out our contact form to schedule a free claim review today.